Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao, Feng Tian, John M Mariadason, Chun C Tsao, Robert Lemos, Farshid Dayyani, YN Vashisht Gopal, Zhi-Qin Jiang, Ignacio I Wistuba, Xi M Tang, William G Bornman, Gideon Bollag, Gordon B Mills, Garth Powis, Jayesh Desai, Gary E Gallick, Michael A Davies, Scott Kopetz
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2013
Awarded by Cancer Center Support Grant
Awarded by NATIONAL CANCER INSTITUTE
The study was supported by CA136980 (S. Kopetz), CA172670 (S. Kopetz and G. Powis), and the Cancer Center Support Grant CA16672, including the Translational Chemistry Core.J.M. Mariadason has commercial research support from Roche Pharmaceuticals. G. B. Mills has commercial research grants from AstraZeneca, Celgene, CeMines, Exelixis/Sanofi, GSK, Roche, and Wyeth/Pfizer/Puma; has ownership interest (including patents) in Catena Pharm, PTV Ventures, and Spindle Top Ventures; and is a consultant/advisory board member of AstraZeneca, Catena Pharm, Tau Therapeutics, Critical Outcome Tech, Daiichi Pharm, Targeted Molecular Diagnostics LLC, Foundation Medicine, Han AlBio Korea, Komen Foundation, Novartis, and Symphogen. J. Desai has a commercial research grant from Roche. M. A. Davies has commercial research grants from GlaxoSmithKline, Genentech, Merck, Astrazeneca, and Oncothyreon and is a consultant/advisory board member of Glaxosmithkline, Novartis, and Genentech. S. Kopetz has a commercial research grant from Roche and is a consultant/advisory board member of Roche and GSK. No potential conflicts of interest were disclosed by the other authors.